Study Pushes Anti-Bleeding Drug off Market
A new study conducted by the Ottawa Health Research Institute provides solid evidence that patients taking the anti-bleeding drug Aprotinin (marketed under the name of Trasylol) are at higher risk of dying from post-surgery complications then those receiving cheaper generic medications.
More than 2 thousand patients from 19 heart-surgery institutions of ...